|
Oct 9
|
WAVE Life Sciences Ltd (WVE) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising ...
|
|
Jun 24
|
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
|
|
Jun 24
|
Takeda reports positive data from Phase IIb trial of ITP treatment
|
|
Jun 24
|
EC approves Takeda’s Fruzaqla for metastatic colorectal cancer
|
|
Jun 24
|
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
|
|
Jun 23
|
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
|
|
Jun 21
|
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
|
|
Jun 21
|
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
|
|
Jun 21
|
Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older
|
|
Jun 19
|
Takeda reports long-term data from Phase III CIDP treatment trial
|
|
Jun 18
|
OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
|
|
Jun 18
|
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
|
|
May 10
|
Catalyst's New CEO Has Big Ideas For The Small Biotech
|
|
May 9
|
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
|
|
May 9
|
Takeda tackles $900m restructuring plan after generics hurt annual profits
|
|
May 9
|
Takeda targets ‘efficiency’ in restructuring, pipeline cuts
|
|
May 9
|
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss
|
|
May 9
|
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
|
|
May 8
|
Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations
|
|
Dec 22
|
One Ultra-Cheap High-Yield Dividend Stock to Buy
|